

**Zydus to present new scientific data on Lipaglyn (Saroglitazar),
and real world data in patients with Type 2 Diabetes at
the American Diabetes Association 75th Scientific Sessions in Boston, USA**

Ahmedabad, India, June 6, 2015

Zydus Cadila, a leading global healthcare provider, today announced that new scientific and clinical data on Saroglitazar will be presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA from 5th to 9th June, 2015. Several analyses of real-world patient data of Saroglitazar will also be presented. The abstracts are available on the ADA website.

Speaking on the development, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus Cadila said, “These new robust scientific data on the safety and efficacy of Lipaglyn (Saroglitazar) being presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) reflect our continued commitment to millions of patients living with Diabetes, Dyslipidemia, Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH).”

Details of posters and presentations on Lipaglyn (saroglitazar) are as follows:

- **Abstract #693-P:** Lipid Lowering Effects of Saroglitazar in Preclinical Models: Potential Synergistic Interaction with Statins. **(Saturday, June 6, 11:30 - 1:30 PM)**
- **Abstract #703-P:** Saroglitazar Shows Beneficial Effects on Insulin Sensitivity, Dyslipidemia, and Blood Pressure in Zucker Fatty Rats. **(Saturday, June 6, 11:30 - 1:30 PM)**
- **Abstract #704-P:** Effect of Saroglitazar, a Dual PPAR- α/γ agonist, on Lipid and Glycemic Parameters in Indian Patients with Diabetic Dyslipidemia—A 27-Week, Retrospective Analysis. **(Saturday, June 6, 11:30 - 1:30 PM)**
- **Abstract #712-P:** To Assess the Effect of 4mg Saroglitazar on Patients of Diabetes Dyslipidemia with Nonalcoholic Fatty Liver Disease for 24 Weeks at Diabetes Care Centre. **(Saturday, June 6, 11:30 - 1:30 PM)**
- **Abstract #1187-P:** Effect of Saroglitazar on Fatty Acid Metabolism in Zucker Fa/Fa Rats **(Sunday, June 7, 12:00 - 2:00 PM)**
- **Abstract #1957-P:** Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) **(Monday, June 8, 12:00 - 2:00 p.m)**

Late Breaking abstracts that will be presented include:

- **Abstract#126-LB:** Saroglitazar in Diabetic Dyslipidemia: 1 year data (**Sunday, June 7, 12:00 - 2:00 PM**)

Importantly, Abstract #693-P: “Lipid Lowering Effects of Saroglitazar in Preclinical Models: Potential Synergistic Interaction with Statins.” has been selected to be showcased in a **Guided Audio Poster Tour** in addition to the general Poster Session presentation. **Poster has been assigned to the tour entitled, Diabetic Dyslipidemia —metabolism and Treatment on Monday, June 8, 2015, 12:00 PM - 1:00 PM.**

About Lipaglyn

LipaglynTM (Saroglitazar) was launched in September 2013 in India, for treating Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. Since then, more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians. LipaglynTM helps in a reduction of triglycerides and LDL (bad) cholesterol, and an increase in HDL (good) cholesterol and has also shown a reduction in Fasting Plasma Glucose and glycosylated haemoglobin (HbA1c), thereby confirming its beneficial effects on both lipid and glycemic control in diabetic patients. LipaglynTM is a prescription medicine, and can be taken only under the advice and guidance of a registered medical practitioner.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 16,500 people worldwide including over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. As a leading healthcare provider, it aims to become a global research based pharmaceutical company by 2020.